Methods for a Community-Engaged Randomized Trial for Urgency Incontinence.

Urogynecology (Phila)Sep 30, 2026 (epub)
Clinical ResearchUrology

Vivian W Sung, Holly E Richter, Emily S Lukacz et al.

✦ AI-curated · Sources linked

In 30 seconds

The Beta-Agonist versus ONA Trial for Urgency Urinary Incontinence (BEST) is a multicenter, single-blinded randomized trial comparing the efficacy of beta-agonist medication and onabotulinumtoxinA injections in female participants with urgency urinary incontinence (UUI). The study aims to assess symptom severity and treatment satisfaction at 3 months, with 432 participants planned for enrollment.

Key findings

  • As of January 6, 2026, 396 of 432 participants (92%) have been randomized.
  • 324 participants (82% of randomized) have reached the primary 3-month outcome.
  • The trial aims to detect a 15% difference in treatment satisfaction and symptom severity.

Why it matters

This trial addresses a significant gap in comparative efficacy data for common treatments of urgency urinary incontinence, which can guide clinicians in making informed treatment decisions based on patient-centered outcomes.

Source

PubMed · PMID 42118972

Published in Urogynecology (Phila). This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Urology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.